IBOGF (Universal Ibogaine) Additional Paid-In Capital: $2.91 Mil(As of Apr. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Universal Ibogaine Additional Paid-In Capital?

Universal Ibogaine IBOGF -99.89% Additional Paid-In Capital is $2.91 Mil as of Apr. 2025.


Universal Ibogaine's quarterly additional paid-in capital declined from Oct. 2024 ($2.89 Mil) to Jan. 2025 ($2.78 Mil) but then increased from Jan. 2025 ($2.78 Mil) to Apr. 2025 ($2.91 Mil).

Universal Ibogaine's annual additional paid-in capital increased from Jul. 2022 ($ Mil) to Jul. 2023 ($3.07 Mil) but then declined from Jul. 2023 ($3.07 Mil) to Jul. 2024 ($2.91 Mil).

Universal Ibogaine Additional Paid-In Capital Related Terms

Universal Ibogaine Additional Paid-In Capital Historical Data

* Premium members only.

The historical data trend for Universal Ibogaine's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Universal Ibogaine Additional Paid-In Capital Chart

Universal Ibogaine Annual Data
Trend Mar18 Mar19 Mar20 Jul21 Jul22 Jul23 Jul24
Additional Paid-In Capital
Get a 7-Day Free Trial 0.07 - - 3.07 2.91

Universal Ibogaine Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.96 2.91 2.89 2.78 2.91

Universal Ibogaine Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)
What does a Additional Paid-In Capital of $2.91 Mil mean?
Universal Ibogaine (IBOGF) has a Additional Paid-In Capital of $2.91 Mil as of Apr. 2025. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Universal Ibogaine and its competitors.
Is Universal Ibogaine's Additional Paid-In Capital too high?
Universal Ibogaine's current Additional Paid-In Capital is $2.91 Mil.
How does Universal Ibogaine's Additional Paid-In Capital compare to LABT and CALC?
Universal Ibogaine's Additional Paid-In Capital of $2.91 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Additional Paid-In Capital for a Biotechnology company?
A good Additional Paid-In Capital depends on the Biotechnology industry context. However, Additional Paid-In Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Additional Paid-In Capital mean?
A high Additional Paid-In Capital can signal that a stock is expensive relative to its fundamentals. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Universal Ibogaine and its competitors. Universal Ibogaine's current Additional Paid-In Capital is $2.91 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Universal Ibogaine stock overvalued right now?
Universal Ibogaine (IBOGF) has a current Additional Paid-In Capital of $2.91 Mil. The current Additional Paid-In Capital is $2.91 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Additional Paid-In Capital calculated?
Additional Paid-In Capital is calculated from a company's financial statements. For Universal Ibogaine (IBOGF), the current Additional Paid-In Capital is $2.91 Mil as of Apr. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Universal Ibogaine Business Description

Address C/o Cas Corporate Governance Services Inc, 815 - 8th Avenue South west, Suite 600, Calgary, AB, CAN, T2P 3P2
Universal Ibogaine Inc is in the initial stages of implementing and financing its business plan, which is to develop a network of addiction treatment clinics and to undertake a planned clinical trial for research in Canada into the use of ibogaine, a natural plant-based substance, for addiction treatment. Its mission is to redefine the addiction recovery experience, providing those living with addiction the best possible recovery.